Document:

Amendment to License, Development and Supply Agreement

    Exhibit
      4.13

    

     

    AMENDMENT
      TO LICENSE, DEVELOPMENT AND SUPPLY AGREEMENT

     

    
      	
              THIS
                AMENDMENT AGREEMENTeffective
                as of December
                9, 2005 is made by and between PREMD
                INC.(previously
                known as IMI
                International Medical Innovations Inc.),
                a corporation incorporated under the laws of Canada, and having its
                principal place of business at Suite 615, 4211 Yonge Street, Toronto,
                Ontario, M2P 2A9, Canada (“PreMD-Canada”),
                PREMD
                INTERNATIONAL INC.(previously
                known as IMI
                International Medical Innovations Inc.,
                a corporation incorporated under the laws of Switzerland, and having
                its
                office c/o Schmid Attorneys at Law, Stockerstrasse 38 Schwanengasse
                1,
                CH-3011 Berne, Switzerland (“PreMD-Switzerland”)
                (PreMD-Canada together with PreMD-Switzerland being herein referred
                to
                collectively as “PreMD”
                or “Party”)
                and McNEIL Consumer & Specialty Pharmaceuticals Division of
                McNEIL-PPC, Inc., incorporated under the laws of the State of New
                Jersey,
                the United States of America, and having its principal place of business
                at 7050 Camp Hill Road, Pennsylvania, PA 19034 (“McNEIL-US”),
                and McNEIL PDI Inc., a corporation incorporated under the laws of
                Canada,
                with and having its principal place of business at 768 Hebert Street,
                Desbiens, Quebec, Canada (acting through its McNEIL Consumer Healthcare
                division) (“McNEIL-Canada”
                )(MCNEIL-US together with MCNEIL-Canada being herein referred to
                collectively as “MCNEIL”
                or “Party”).
                McNEIL
                and PreMD may also be referred to as“Parties.”

            

    

    
Whereas:

    A. The
      Parties are parties to a License, Development And Supply Agreement dated as
      of
      May 28th,
      2004 (the “International
      Agreement”);

    B.
       The
      Parties wish to waive certain rights and obligations that they may have pursuant
      to certain provisions contained in the Agreement and to amend the provisions
      of
      the Agreement, in each case as specifically contemplated herein;
      and

    C. Capitalized
      terms used herein which are not otherwise defined shall have their respective
      meanings ascribed thereto in the Agreement. 

    

    NOW,
      THEREFORE, in consideration of the mutual covenants and obligations contained
      herein and for other good and valuable consideration, the receipt and
      sufficiency of which is hereby acknowledged, the Parties agree as
      follows:

    Sales
      Minimums

    
      	 	
              1.

            	
              PreMD
                hereby waives any rights which it may have as a result of McNeil’s not
                having cumulative Net Sales of Products pursuant to section 17.3(a)
                for
                the 2004, 2005 and 2006 Calendar Years (it being understood that
                the
                obligations of McNeil pursuant to section 17.3(a) shall arise only
                in
                respect of the 2007 and subsequent Calendar Years), subject to the
                ability
                of McNeil to ***** provided for in section 17.3 of the Agreement.
                

            

    

    
    

     

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      	 	
              2.

            	
              PreMD
                hereby waives any rights which it may have as a result of McNeil’s not
                having cumulative Net Sales of Products pursuant to section 17.3
                (b) for
                the 2004 and 2005 Calendar Years (it being understood that the obligations
                of McNeil pursuant to section 17.3(b) shall arise only in respect
                of the
                2006 and subsequent Calendar Years), subject to the ability of McNeil
                to
                ***** provided for in section 17.3 of the Agreement.
                

            

    

    
      	 	
              3.

            	
              For
                greater certainty, it is understood and agreed that McNeil
                *****
                in respect of obligations arising
                under:

            

    

    
      	 	
              a.

            	
              Subsection
                17.3(a), commencing in 2007; and

            

    

    
      	 	
              b.

            	
              Subsection
                17.3(b) commencing in 2006.

            

    

    US
      Patent Matters

    
      	 	
              4.

            	
              In
                the event that both US Patent No. 5,489,510 and US Patent No. 5,587,295
                (collectively, the “Expired Patents”)
                are not reinstated by the United States Patent Office by 1
                August in a given Calendar Year, then the reference subsection 17.3(a)
                to
                ***** in respect of such Calendar Year shall be read as
                *****.

            

      	 	5.	
              In
                the event that one but not both of the Expired Patents is reinstated
                by
                the United States Patent Office by 1
                August in a given Calendar Year, then the reference subsection 17.3(a)
                to
                ***** in respect of such Calendar Year shall be read as
                *****.

            

    

    

    

    *****

    
      	 	
              6.

            	
              The
                provisions of section 8.7 of the Agreement (other than the first
                sentence
                thereof) shall not apply in respect of the Product in circumstances
                where
                the Product is *****,
                the specifications of which are identified in Appendix “A” hereto.
                *****
                as contemplated in section 8.1 of the Agreement.
                *****
                and development work results in a lower *****.

            

    

    
      	 	
              7.

            	
              Notwithstanding
                the provisions of section 6 of this amending agreement, in the event
                that
                the specifications for the *****
                (a)
                change from those identified on Appendix A as a result of additional
                development costs *****.
                For
                example, if subsequent development efforts are required *****, then
                the
                going forward *****

            

    

    
      	 	
              a)

            	
              *****

            

    

    
      	 	
              b)

            	
              *****

            

    

    
      	 	
              c)

            	
              *****

            

    

    

    
      	 	
              8.

            	
              PreMD
                agrees to use commercially reasonable efforts,
                which for purposes of clarity may, at a minimum, include the need
                to
                expend funds or make payments (other than PreMD’s attorneys fees and any
                other PreMD’s out-of-pocket expenses in connection with the negotiations
                thereof) of up to ***** to
                renegotiate the development agreement with ***** (such agreement,
                as
                amended from time to time, being herein referred to as the *****
                to
                further define the rights of PreMD in Collaboration IP *****
                in the
                event that intellectual property is created during development
                work
                in order to provide that PreMD will be granted a worldwide, irrevocable,
                royalty-free, non-exclusive license, with the right to grant a sublicense,
                to use and sell Design Elements
                *****.

            

    

     

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      	 	
              8.1

            	
              In
                the event that the amount of payment required to obtain the rights
                set
                forth in this Paragraph exceeds the amount of the ***** shall be
                responsible for any additional payment ***** (other than attorneys
                fees
                and any other out-of-pocket expenses in connection with the negotiations
                thereof) *****. 

            

    

    
      	 	
              8.2

            	
              In
                the event that the amount of payment required to obtain the rights
                set
                forth in this Paragraph exceeds a total of ***** responsible for
                any
                additional payment ***** (other than attorneys fees and any other
                out-of-pocket expenses in connection with the negotiations thereof)
                *****.
                

            

    

    
      	 	
              8.3

            	
              In
                the event that the amount of payment required to obtain the rights
                set
                forth in this Paragraph exceeds a total of ***** discuss their respective
                payment responsibilities for the amount, if any, that may be due
                *****
                (but, for greater certainty, no Party shall be required to make any
                payment under Section 8.3 unless **** to do
                so).

            

    

    
      	 	
              8.4

            	
              Each
                party shall be responsible for the payment of their own, respective,
                attorneys fees and out of pocket expenses that it may incur in connection
                with the negotiations as set forth in this Section 8.

            

    

     

    Royalty
      on ***** Sales

    
      	 	
              9.

            	
              The
                parties acknowledge and agree that for the purposes of provisions
                of
                Article IV of the Agreement the Net Sales of the Product are to include
                any Net Sales attributed to the sales of
                *****.

            

    

    

    *****-
      PreMD Collaboration IP

    
      	 	
              10.

            	
              To
                the extent commercially practicable, PreMD shall offer to include
                a
                designated representative of McNeil (the “McNeil
                Designate”)
                in all meetings with ***** and persons from whom ***** licenses any
                patents or rights to patent applications to the extent that such
                meetings
                relate to Collaboration IP *****, in all cases to the extent that
                McNeil
                shall wish to participate in such meetings. PreMD shall provide the
                McNeil
                Designate with such advance notice of such meetings as PreMD shall
                have
                received and PreMD shall use commercially reasonable efforts to schedule
                such meetings at least 48 hours after notice of such meeting has
                been
                provided to the McNeil Designate. McNeil acknowledges that this advance
                notice shall not always be possible, and that the obligations of
                PreMD
                under this section 10 shall
                be subject to PreMD’s need and desire to proceed with meetings with such
                persons on a commercially reasonable and timely and efficient basis.
                If
                such a meeting occurs and McNeil has not been provided with such
                advance
                notice, PreMD will as soon as reasonably practicable after such meeting
                provide the McNeil Designate with a summary of the material matters
                discussed and agreed upon at such
                meeting.

            

    

    
    

     

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      	 	
              11.

            	
              Subject
                to compliance with the terms and conditions of the *****, the parties
                agree that the Collaboration IP shall be considered as IMI Improvement
                Intellectual Property under Section 2.5.4 of the International
                Agreement.

            

    

    
      	 	
              12.

            	
              The
                provisions of 14.1 and 14.2 of the Agreement shall apply in respect
                of the
                Collaboration IP.

            

    

    

    Milestone
      Payments

    
      	 	
              13.

            	 

    

    
      	 	
              a.

            	
              McNeil
                shall pay PreMD-Canada a payment of 1) ***** upon completion of the
                Principal Design Review Meetings (within the meaning of the *****);
                and 2)
                ***** upon completion of the Critical Design Review Meeting (within
                the
                meaning of the ***** in consideration of IMI’s costs incurred in
                developing the ***** and for McNEIL’s right to obtain a ***** unit cost
                pursuant to Paragraphs 7 and 8 herein.

            

    

    

    Miscellaneous

    
      	 	
              14.

            	
              In
                all other respects, the terms and conditions of the Agreement shall
                remain
                in full force and effect,
                unamended.

            

    

    
      	 	
              15.

            	
              The
                provisions of sections 19.4 and 19.7 shall apply, mutatis
                mutandis,
                to this amending agreement. 

            

    

     

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    IN
      WITNESS WHEREOF, the Parties have duly executed this Agreement as of the day
      and
      year first written above. 

    

    MCNEIL
      PDI INC.

    (acting
      through its McNEIL Consumer Healthcare

    division
      on behalf of McNEIL PDI Inc.)

    

    By:
      /s/______________________

    Name:

    Title:

    Authorized
      Signing Officer

    

    MCNEIL
      CONSUMER & SPECIALTY PHARMACEUTICAL DIVISION OF MCNEIL-PPC,
      INC.

    

    By:
      /s/______________________

    Name:

    Title:

    Authorized
      Signing Officer

    

    PREMD
      INC.

    A
      Canadian corporation

    

    By:
      /s/______________________

    Name:

    Title:

    Authorized
      Signing Officer

    PREMD
      INTERNATIONAL INC.

    A
      Swiss corporation

    

    By:
      /s/______________________

    Name:

    Title:

    Authorized
      Signing OfficerEX-10.1

Exhibit 10.1

EMPLOYMENT AGREEMENT

This EMPLOYMENT AGREEMENT (“Agreement”), dated as of August 7, 2006 (the “Effective
Date”), is made by and between AVANIR PHARMACEUTICALS, a California corporation having its
principal offices at 101 Enterprise, Suite 300, Aliso Viejo, California, 92656 (the
"Company”), and Theresa Hope-Reese (“Employee”).

AGREEMENT

1. Commencement Date.

Employee’s employment under this Agreement shall commence on August 7, 2006 (“Commencement
Date”).

2. At-will Employment.

Employee’s employment relationship with the Company (“Employment”) is at-will,
terminable at any time with or without cause or advance notice by either the Company or Employee.
While certain sections of this Agreement describe events that could occur at a particular time in
the future, nothing in this Agreement shall be construed as a guarantee of employment of any
length.

3. Employment Duties.

(a) Title. Employee shall be Vice President of Human Resources of the Company and
shall be assigned duties and responsibilities consistent with that position at the discretion of
the Company.

(b) Full-Time Attention. Employee shall devote her full time, attention, energy and
skills to the Company during the period she is employed under this Agreement.

(c) Policy Compliance. Employee shall comply with all of the Company’s policies,
practices and procedures, including the terms of the Confidentiality Agreement (defined below).

4. Compensation.

(a) Base Salary. The Company shall pay Employee a base salary of $18,333.33 per month
(an annual rate of $220,000), or such higher amount as the Company may determine from time to time
(“Base Salary”), payable in accordance with the Company’s regular payroll practices.

(b) Bonus Compensation. In addition to the Base Salary, Employee shall be eligible
for an annual discretionary bonus of up to 30% of the Employee’s then-current annual base salary
(pro-rated for fiscal 2006 as described below), with such bonus to be determined and paid in the
first quarter of each fiscal year with respect to Employee and Company performance in the prior
fiscal year. The actual bonus may be higher or lower than the 30% target amount, at the
discretion of the Company. Any bonus payable with regard to performance in fiscal 2006 will be
prorated on account of Employee’s commencement of employment less than one year prior to the
payment date. Employee must be employed by the Company when bonuses are distributed in order to be
eligible to receive such bonus. If Employee leaves the employ of the Company for any reason prior
to the distribution of annual bonuses in any given year, she will not be eligible to receive any
part of that year’s discretionary bonus.

(c) Equity Compensation. The Company will recommend to its Board of Directors that
Employee be granted the following equity awards as additional compensation:

(i) Subject to Board approval and the commencement of employment, Employee shall be granted
the right to purchase 6,000 shares of Class A common stock (the “Restricted Shares”) at a
purchase price of $0.001 per share. The Restricted Shares shall vest in full upon Employee’s
completion of two full years of employment (the “Vesting Date”). The Restricted Shares will be
granted pursuant to the Company’s equity compensation plans (the “Equity Plans”) and will be
governed by the terms and conditions of such plans. Subject to Section 10(d) of this Agreement,
the Restricted Shares may be repurchased by the Company in accordance with the Equity Plans if the
Employment is terminated prior to the Vesting Date.

(ii) Subject to Board approval and the commencement of employment, Employee shall be granted
an option to purchase 40,000 shares of Class A common stock, with an exercise price equal to 100%
of the fair market value of the underlying shares on the date of grant, subject to a four-year
vesting schedule (25% vesting on the first anniversary of the Commencement Date and the remainder
vesting in 12 equal installments each quarter thereafter over the next three years). This option
shall be granted pursuant to the Equity Plans and shall be subject to the terms and conditions of
such plans. This option is intended to be an incentive stock option under Section 422 of the
Internal Revenue Code of 1986, as amended (the “Code”) to the fullest extent permitted, and any
excess will be treated as a non-statutory stock option. The Company has no responsibility as to
actual tax treatment, however.

The foregoing share amounts and share purchase prices shall be adjusted, as necessary, to give
effect to any stock split, reverse stock split, stock dividend, recapitalization or similar
transaction affecting the Company’s Class A common stock that is effected after the Effective Date.

(d) Employee Benefits. Employee shall be entitled to participate in all employee
benefit plans, programs and arrangements maintained by the Company and made available to employees
generally. The Employee’s participation in such Company plans or programs shall be on the same
basis and terms as are applicable to other executive employees of the Company. Employee shall
accrue 4 weeks of vacation the first year of service.

(e) Reimbursement of Expenses. During her employment with the Company, Employee shall
be entitled to reimbursement for all reasonable and necessary business expenses incurred on behalf
of the Company, in accordance with the Company’s policies and procedures.

5. Confidentiality Agreement. Employee shall concurrently herewith execute and
deliver to the Company the Employee Invention Assignment, Patent and Confidential Information
Agreement (“Confidentiality Agreement”) in the form attached hereto as Exhibit B.

6. Non-Competition. During her Employment, Employee shall not, directly or
indirectly, either as an employee, employer, consultant, corporate officer or director, investor,
or in any other capacity, engage or participate in any business that is a Competitor of the
Company, unless such participation or interest is fully disclosed to the Company and approved by
the Board. “Competitor” as used in this paragraph refers to any company that has therapeutic
products (i) on the market or in clinical development and (ii) that are in competition with the
products the Company has on the market or that have entered clinical development. Notwithstanding
the above, Employee may own securities in any Competitor that is a public company, so long as
Employee does not own, of record or beneficially, more than an aggregate of five percent of the
outstanding securities of such company.

7. Non-Solicitation. During her Employment, and for a period of 12 months thereafter,
whether for Employee’s own account or the account of any other person, Employee shall not solicit,
directly or indirectly, any employee to leave her or her employment with the Company. For purposes
of this Agreement, the phrase, “shall not solicit, directly or indirectly,” includes, without
limitation, that Employee shall not: (i) identify any Company employees to any third party as
potential candidates for employment, such as by disclosing the names, backgrounds, compensation or
qualifications of any Company employees; (ii) personally or through any other person approach,
recruit or otherwise solicit employees of Company to work for any other employer; or (iii)
participate in any pre-employment interview with any person who was employed by the Company while
Employee was employed by the Company whether under this Agreement or otherwise.

8. Agreement with Previous Employers. Employee represents and warrants to the Company
that she does not have any agreement with any previous employer that prevents her from performing
her duties and responsibilities under this Agreement or that in any way limits her performance
hereunder. Employee understands and acknowledges that her employment with Avanir is contingent
upon her compliance with any and all agreements between her and her prior employers.

9. Change of Control. Upon commencement of employment, Employee shall be eligible to
enter into the Company’s standard Change of Control Agreement for executive officers (the “Change
of Control Agreement”) in the form attached hereto as Exhibit A.

10. Voluntary Resignation or Termination for “Cause.”

(a) Payment upon Voluntary Resignation or Termination for Cause. If Employee
voluntarily resigns her Employment, and such resignation is not a “Resignation for Good Reason” (as
defined in the Change of Control Agreement), or if Employee is terminated for Cause (defined
below), the Company shall pay Employee all accrued and unpaid Base Salary through the date of
termination and any vacation that is accrued but unused as of such date. Employee shall not be
eligible for Severance Payments, as defined below, or any continuation of benefits (other than
those provided for under the Federal Consolidated Omnibus Budget Reconciliation Act
(“COBRA”)), or any other compensation pursuant to this Agreement or otherwise.

(b) Definition of “Cause.” As set forth above, the Employment relationship between
the parties is at-will, terminable at any time by either party for any reason or no reason. The
termination may nonetheless be for “Cause.” For purposes of this Agreement,
“Cause” means:

(i) Employee’s material breach of this Agreement or any confidentiality agreement between the
Company and Employee; or

(ii) Employee’s willful and intentional failure or refusal to comply with the Company’s
Employee Manual, the Company’s Code of Business Conduct and Ethics, or other policies or procedures
established by the Company; or

(iii) Employee’s willful and intentional appropriation (or attempted appropriation) of a
material business opportunity of the Company, including attempting to secure or securing any
personal profit in connection with any transaction entered into on behalf of the Company; or

(iv) Employee’s misappropriation (or attempted misappropriation) of any of the Company’s funds
or material property; or

(v) Employee’s conviction of, or the entering of a guilty plea or plea of no contest with
respect to a felony, the equivalent thereof, or any other crime with respect to which imprisonment
is a possible punishment; or

(vi) Employee’s willful and intentional misconduct or incompetence; or

(vii) Employee’s becoming “disabled,” (defined in Section 409A(a)(2)(C) of the Code),
resulting in her inability to perform the essential functions of her position, with reasonable
accommodation; or

(viii) Employee’s death.

(c) In each case, “Cause” shall be determined conclusively by the Board, acting in good faith.
Notwithstanding the foregoing, no event described in Section 10(b)(i), (ii), (iii) and (vi) above
will give rise to “Cause” unless it is communicated by the Company to Employee in writing and
unless it is not corrected by the Employee in a manner that is reasonable satisfactory to Company
within 30 days of the Employee’s receipt of such written notice.

(d) Termination Without Cause or Resignation for Good Reason. Subject to Section 9,
if Employee: (i) is terminated without “Cause,” or (ii) resigns in a “Resignation for Good Reason,”
(as defined in the Change of Control Agreement), then Employee shall be paid all accrued and unpaid
Base Salary and any accrued but unused vacation through the date of termination. In addition, in
exchange for Employee’s execution of a release of all claims against the Company and its
subsidiaries and affiliates effective as of the date of termination and in substantially the form
attached to the Change of Control Agreement:

(i) Employee shall be eligible to receive severance payments under this Agreement in an amount
equal to six months Base Salary and an amount equal to the greater of (x) 15% of Base Salary or
(y) 50% of the last bonus, if any, paid to Employee pursuant to Section 4 (the “Severance
Payments”), payable on the earliest of (A) the date that is six months and a day after
Employee’s “separation from service” for any reason, other than death or becoming “disabled” (as
such terms are used in Section 409A(a)(2) of the Code), (B) the date of Employee’s death or on
which Employee becomes “disabled” (as such term is used in Section 409A(a)(2)(C) of the Code), (C)
the effective date of a “change in the ownership or effective control” of the Company (as such term
is used in Section 409A(a)(2)(A)(v) of the Code) or (D) the date such payments or benefits are no
longer deemed by the Code to be subject to penalty tax or interest. The provisions of this
paragraph shall only apply to the extent required to avoid Employee’s incurrence of any penalty tax
or interest under Section 409A of the Code or any regulations or Treasury guidance promulgated
thereunder. In addition, if any provision of this Agreement would cause Employee to incur any
penalty tax or interest under Section 409A of the Code or any regulations or Treasury guidance
promulgated thereunder, the Company shall, upon the written request of Employee, reform such
provision to maintain to the maximum extent practicable the original intent of the applicable
provision without violating the provisions of Section 409A of the Code and without creating
additional cost for the Company; and

(ii) the Company’s right to repurchase the Restricted Shares under the Equity Plans shall
lapse and Employee’s ownership of the Restricted Shares shall be fully vested.

11. Dispute Resolution Procedures. Except as expressly provided in this Agreement,
Employee agrees that any dispute or controversy arising out of, relating to, or in connection with
this Agreement, or the interpretation, validity, construction, performance, breach, or termination
thereof shall be settled by arbitration, to the extent permitted by law, to be held in Orange
County, California in accordance with the National Rules for the Resolution of Employment Disputes
then in effect of the American Arbitration Association (the “Rules”) and in accordance with
the accompanying Mutual Arbitration Agreement attached hereto as Exhibit C. The
arbitrator’s decision shall be final, conclusive and binding on the parties to the arbitration
pursuant to the Mutual Arbitration Agreement. Judgment may be entered on the decision of the
arbitrator in any court having competent jurisdiction.

12. Notices. Any reports, notices or other communications required or permitted to be
given by either party hereto, shall be given in writing by personal delivery, overnight courier
service, or by registered or certified mail, postage prepaid, return receipt requested, addressed
to each respective party at the address shown below or other current address:

If to AVANIR:

Avanir Pharmaceuticals

101 Enterprise, Suite 300

Aliso Viejo, California 92656

Attn: Chief Executive Officer

If to Employee:

Theresa Hope-Reese

[Address]

13. Withholding. All payments, including Base Salary, bonus and Severance Payments,
shall be paid less applicable Federal and state withholding taxes. In the case of the rights
referred to in Section 4(c) (Equity Compensation) above, Employee shall be responsible for
furnishing the Company with the amount of any required withholding at the time it is due, and the
Company’s obligations with respect to such rights shall be conditioned upon Employee’s compliance
with this Section 13.

14. General Provisions.

(a) Governing Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of California.

(b) Assignment. Employee may not assign, pledge or encumber her interest in this
Agreement or any part thereof.

(c) No Waiver of Breach. The failure to enforce any provision of this Agreement shall
not be construed as a waiver of any such provision, nor prevent a party thereafter from enforcing
the provision or any other provision of this Agreement. The rights granted the parties are
cumulative, and the election of one shall not constitute a waiver of such party’s right to assert
all other legal and equitable remedies available under the circumstances.

(d) Severability. The provisions of this Agreement are severable, and if any
provision shall be held to be invalid or otherwise unenforceable, in whole or in part, the
remainder of the provisions, or enforceable parts of this Agreement, shall not be affected.

(e) Entire Agreement. This Agreement and the exhibits hereto constitute the entire
agreement of the parties with respect to the subject matter of this Agreement and supersedes all
prior and contemporaneous negotiations, agreements and understandings between the parties, whether
oral or written.

(f) Modifications and Waivers. No modification or waiver of this Agreement shall be
valid unless in writing, signed by the party against whom such modification or waiver is sought to
be enforced.

(g) Amendment. This Agreement may be amended or supplemented only by a writing signed
by both of the parties hereto.

(h) Duplicate Counterparts. This Agreement may be executed in duplicate counterparts,
each of which shall be deemed an original; provided, however, such counterparts shall together
constitute only one agreement.

(i) Interpretation. The headings contained in this Agreement are for reference
purposes only and shall not affect in any way the meaning or interpretation of this Agreement.

(j) Drafting Ambiguities. Each party to this Agreement and its counsel have reviewed
and revised this Agreement. The rule of construction that any ambiguities are to be resolved
against the drafting party shall not be employed in the interpretation of this Agreement or any of
the amendments to this Agreement.

* * *

1

EXECUTED at Aliso Viejo, California, this      day of August, 2006.

AVANIR PHARMACEUTICALS

	 	 	 
	Dated: August 3, 2006

	 	By: /s/ Eric K. Brandt     
	
 
	 	 
	
 
	 	Eric K. Brandt

Chief Executive Officer
	 
	 	 
	
 
	 	EMPLOYEE
	 
	 	 
	Dated: August 3, 2006

	 	/s/ Theresa Hope-Reese     
	
 
	 	 
	 
	 	 
	
 
	 	Theresa Hope-Reese
	 
	 	 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]